Evidence map›Paper›PMID 27239111›Full record

ArticleWorld journal of gastroenterology2016

Immunological changes in different patient populations with chronic hepatitis C virus infection.

Laszlo Szereday, Matyas Meggyes, Melinda Halasz, Julia Szekeres-Bartho, Alajos Par, Gabriella Par

Open access · hybridAbstract read
In one paragraph

Article in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Laszlo SzeredayLaszlo Szereday, Matyas Meggyes, Melinda Halasz, Julia Szekeres-Bartho, Department of Medical Microbiology and Immunology, University of Pecs, Clinical Centre, 7624 Pecs, Hungary.
Matyas MeggyesLaszlo Szereday, Matyas Meggyes, Melinda Halasz, Julia Szekeres-Bartho, Department of Medical Microbiology and Immunology, University of Pecs, Clinical Centre, 7624 Pecs, Hungary.
Melinda HalaszLaszlo Szereday, Matyas Meggyes, Melinda Halasz, Julia Szekeres-Bartho, Department of Medical Microbiology and Immunology, University of Pecs, Clinical Centre, 7624 Pecs, Hungary.
Julia Szekeres-BarthoLaszlo Szereday, Matyas Meggyes, Melinda Halasz, Julia Szekeres-Bartho, Department of Medical Microbiology and Immunology, University of Pecs, Clinical Centre, 7624 Pecs, Hungary.
Alajos ParLaszlo Szereday, Matyas Meggyes, Melinda Halasz, Julia Szekeres-Bartho, Department of Medical Microbiology and Immunology, University of Pecs, Clinical Centre, 7624 Pecs, Hungary.
Gabriella ParLaszlo Szereday, Matyas Meggyes, Melinda Halasz, Julia Szekeres-Bartho, Department of Medical Microbiology and Immunology, University of Pecs, Clinical Centre, 7624 Pecs, Hungary.
University of Pecs · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo investigate killer inhibitory and activating receptor expression by natural killer (NK), natural killer T-like (NKT-like) and CD8+ T lymphocytes in patients with chronic hepatitis C virus (HCV) infection with elevated and with persistently normal alanine aminotransferase (PNALT).

methodsThe percentage of peripheral blood Treg cells, KIR2DL3, ILT-2, KIR3DL1, CD160, NKG2D, NKG2C expressing NK, T and NKT-like cells, cytokine production and NK cytotoxicity were determined by flow cytometry. Twenty-one patients with chronic HCV infection with elevated alanine aminotransferase, 11 HCV carriers with persistently normal alanine aminotransferase and 15 healthy volunteers were enrolled.

resultsNo significant differences were observed in the percentage of total T, NK or NKT-like cells between study groups. Comparing the activating and inhibitory receptor expression by NK cells obtained from HCV carriers with PNALT and chronic HCV hepatitis patients with elevated alanine aminotransferase, NKG2D activating receptor expression was the only receptor showing a significant difference. NKG2D expression of NK cells was significantly lower in patients with elevated alanine aminotransferase. The expression of CD160, NKG2D and NKG2C activating receptor by CD8+ T cells were significantly lower in patients with chronic HCV hepatitis than in healthy controls and in HCV carriers with PNALT. Plasma TGF-β1 levels inversely correlated with NKG2D expression by NK cells. In vitroTGF-β1 treatment inhibited NK cells cytotoxic activity and downregulated NKG2D expression. CD8+ T cells from HCV carriers with PNALT showed significantly elevated expression of CD160, NKG2D and NKG2C activating receptors compared to chronic HCV patients with elevated alanine aminotransferase. Enhanced expression of inhibitory KIR2DL3 receptor, and decreased ILT-2 expression on NK cells were also found in chronic hepatitis C patients compared to healthy controls.

conclusionOur study demonstrated a complex dysregulation of activating and inhibitory receptor expression, such as decreased NKG2D and CD160 activating receptor expression and increased KIR2DL3 inhibitory receptor expression by NK and cytotoxic T cells and may provide further mechanism contributing to defective cellular immune functions in chronic hepatitis C. Increased NKG2D receptor expression in HCV patients with persistently normal ALT suggests an important pathway for sustaining NK and CD8 T cell function and a protective role against disease progression.

Indexed as

AdultAgedAlanine TransaminaseBiomarkersCase-Control StudiesCD8-Positive T-LymphocytesCytokinesCytotoxicity, ImmunologicFemaleHepacivirusHepatitis C, ChronicHost-Pathogen InteractionsHumansKiller Cells, NaturalMaleMiddle AgedAlanine TransaminaseBiomarkersCytokinesReceptors, ImmunologicCytokineCytotoxicityHepatitis CNatural killer cellNKG2D

Identifiers

PMID27239111
PMCPMC4873877
OpenAlexW2396625423

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.